Bids are Invited For LIGNOCAINE,LIGNOJELLY,COLD PLUS,DICLOSPR,NAPROXEN,FEBUXOSTAT,CETRIZINE,LEVOM,PREGABM,BILASTINE,LEVE in SOUTH ANDAMAN, ANDAMAN & NICOBAR

The eligibility requirements include being a registered entity, having experience in supplying medicinal products, and compliance with pertinent health regulations. Bidder documentation must reflect adherence to quality standards and relevant certifications.

Bidders must provide quality assurance certifications, regulatory compliance documents (such as WHO-GMP), and any specific medicinal product approvals mandated by respective health authorities that qualify them for participation in this tender.

To register, bidders must create an account on the Government e-Marketplace (GEM) portal and follow their guided process for submitting bids. Complete all requested details in the application to ensure proper validation.

Bidders should submit documents in formats specified in the tender guidelines, commonly accepted formats include PDF and Word documents. Ensure all files are legible and complete to avoid disqualification.

The technical specifications require that all medicines must conform to the highest quality standards as regulated by health authorities. Detailed descriptions of the manufacturing process, batch number, and shelf life should be provided for each item.

Yes, all medicines must meet prescribed industry standards and be validated through appropriate quality certificates such as ISO or equivalent, ensuring compliance with national and international guidelines.

Bidders must comply with all relevant health and safety regulations imposed by governing bodies, along with furnishing required documentation verifying adherence to compliance standards during the tender evaluation.

Bidder’s products must pass quality testing as specified in the tender documents, and any deviations or non-compliance will result in disqualification. Regular quality assessments may also be required post-delivery.

The Earnest Money Deposit (EMD) required for this tender is INR 40,000, which must be submitted along with the bid submission. This amount will be refunded to non-successful bidders after the completion of the evaluation process.

A performance security of a stipulated percentage of the contract value may be required post-award. Details regarding the exact amount and deposit process will be included in the final awarding documentation.

Payment terms generally adhere to predetermined intervals upon successful delivery and acceptance of the pharmaceuticals, ensuring all quality checks have cleared prior to payment processing.

Price evaluations will consider the total value of each bid submitted, with a comprehensive analysis aimed at ensuring economic viability combined with quality assurance for the offered medicinal products.

All submissions must be made electronically through the Government e-Marketplace (GEM) portal, ensuring timely and secure delivery of required documentation.

Successful bidders will receive a notification post-evaluation through the GEM portal, outlining the results and next steps in the contract awarding process.

Yes, special provisions may be in place to support Micro, Small, and Medium Enterprises (MSEs), which could include financial incentives and relaxed conditions to encourage participation.

Startups may receive additional benefits outlined in the tender documentation, geared towards encouraging innovative solutions and participation within the framework of public procurement processes.

Yes, the tender is aligned with 'Make in India' policies, encouraging local procurement and the utilization of domestic production capabilities within the pharmaceutical sector.

Details of local content specifications required for the offered medicines are provided within the tender, emphasizing the compliance with relevant regulations to foster domestic manufacturing and support local economies.